BioSpace News Archive

Neovasc, Inc. ( NASDAQ , TSX : NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and minimally invasive devices for the treatment of refractory angina, today announced that it will report financial results for the quarter ended March 31, 2020 after the market close on May 7, 2020. Neovasc Chief Executive Officer Fred Colen and Chief Financial Offi

April 23, 2020 12:15 UTC - Non-Invasive, Blood-Based Test Could Help Inform Key Treatment Decisions - SOUTH SAN FRANCISCO, Calif. & NEW HAVEN, Conn.--( BUSINESS WIRE )-- Veracyte, Inc. (Nasdaq: VCYT) and Yale University today announced an exclusive licensing agreement to advance the first genomic test for predicting disease progression in patients with idiopathic pulmonary fibrosis (IPF). The agreement gives Veracyte rights to a 52-gene signature developed by Yale

Daxor Corporation, an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, announced that the United States Department of Defense has awarded the Company a $1.1 million contract for the development and deployment of a small, portable, highly accurate, battery-powered Blood Volume Analyzer.

Reaction Biology Corporation (“RBC”), a US-based preclinical CRO with offices in Pennsylvania and Germany , and PharmaCore Labs (PCL) Co., Ltd, a Chinese firm with offices in Haimen, China , today announced a joint collaboration agreement in China. Under the terms of the agreement, PCL will supply business sup

CRH Medical Corporation is pleased to announce that it has appointed Brian Griffin to its Board of Directors, increasing the size of the Board to five members, effective immediately.

Expansion of BARDA funding will help fund Cytovale pilot study for innovative rapid sepsis diagnostic system that delivers results in under 10 minutes The pilot study will be conducted in partnership with Louisiana State University (LSU) and Our Lady of the Lake Regional Medical Center in Baton Rouge, LA COVID-19 patients are at high risk for sepsis, a f

Partnership will enable Fujitsu customers to access ACCELQ’s cloud-based test automation platform to support growth, scale and innovation

Verastem, Inc., a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, announced that it has appointed John H. Johnson to its Board of Directors.

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has received positive feedback from the U.S. Food and Drug Administration (“FDA”) in response to the Company’s Pre-Investigational New Drug (“pre-IND”) meeting that was announced on April 3, 2020. The FDA recommended that the Company pro

Neutralization of Soluble TNF may decrease progression of breast cancer and lessen resistance to breast cancer immunotherapy